| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net in...
Theratechnologies (NASDAQ:THTX) reported quarterly sales of $22.02 million which beat the analyst consensus estimate of $21.71 ...
In an updated analysis from Parts 1 and 2 of an ongoing Phase 1 clinical trial, sudocetaxel zendusortide induced durable diseas...
Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0...
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share ...
In a poster session at the 2024 annual meeting of the American Association for Cancer Research (AACR) in San Diego, Calif., res...
